Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) is a publicly traded Healthcare sector company. As of May 21, 2026, MRVI trades at $4.42 with a market cap of $601.83M and a P/E ratio of -6.04. MRVI moved +4.98% today. Year to date, MRVI is +16.89%; over the trailing twelve months it is +84.58%. Its 52-week range spans $1.67 to $8.54. Analyst consensus is buy with an average price target of $4.82. Rallies surfaces MRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Maravai LifeSciences Q4 Loss Narrows to $0.04; Revenue Beats at $49.87M: Maravai LifeSciences reported a Q4 adjusted loss of $0.04 per share, beating the consensus estimate of a $0.07 loss by 40%. Revenue for the quarter was $49.87 million, surpassing estimates by 1.21% but down from $56.56 million a year ago.
| Metric | Value |
|---|---|
| Price | $4.42 |
| Market Cap | $601.83M |
| P/E Ratio | -6.04 |
| EPS | $-0.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.54 |
| 52-Week Low | $1.67 |
| Volume | 1.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $204.73M |
| Net Income | $-184.29M |
| Gross Margin | 29.29% |
7 analysts cover MRVI: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.82.